Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
Chiara Cremolini
Consultant or Advisory Role - Bayer; Roche
Fotios Loupakis
Consultant or Advisory Role - Amgen; Bayer; Roche
Lisa Salvatore
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Francesca Battaglin
No relevant relationships to disclose
Teresa Gamucci
No relevant relationships to disclose
Roberta Grande
No relevant relationships to disclose
Francesca Di Fabio
No relevant relationships to disclose
Fabiola Lorena Rojas Llimpe
No relevant relationships to disclose
Laura Ferrari
No relevant relationships to disclose
Mariaelena Casagrande
No relevant relationships to disclose
Sara Lucchesi
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose
Maria Banzi
No relevant relationships to disclose
Chiara Valsuani
No relevant relationships to disclose
Domenico C. Corsi
No relevant relationships to disclose
Gabriella Fontanini
No relevant relationships to disclose
Daniela Tomcikova
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi
Honoraria - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi
Research Funding - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi